Close search filters
Changing filters will change the listed Success Criteria and Techniques
Category
Topic
Search results (26)
Article
PBMs and the drug pipeline: Anticipating tomorrow while affording today
October 04, 2024
Article
Outcomes 2024: How Evernorth manages the drug pipeline today and prepares for tomorrow
May 08, 2024
Article
Innovation in hemophilia drug development and cost-efficiency tools
May 24, 2023
As treatment for hemophilia evolves, data proves a good specialty pharmacy partner can help minimize waste and drive efficient practices.
Article
Three specialty drug trends to prepare for: Biosimilars, gene and cell therapies, cancer drugs
April 20, 2022
Biosimilars, gene and cell therapies, and cancer drugs are filling the specialty pipeline. Here are some insights for each category to help you stay informed.
This topic was the focus of a breakout...
Article
Simplifying medical benefit drug management complexities
July 20, 2022
An integrated approach to managing medically billed specialty drugs is key to optimizing cost savings and clinical outcomes.
Article
The importance of utilization management within the medical benefit
August 17, 2023
The ever-evolving complexity of medications billed through the medical benefit requires continuous investment in processes to manage their increasingly high price tag.
Article
Pharmacy in Focus
October 09, 2023
See the future taking shape in pharmacy and how you can capitalize and prepare for 2024 and beyond.
Article
How Evernorth supports specialty patients living with rare diseases
January 22, 2025
Accredo, which is Evernorth’s industry-leading specialty pharmacy, offers decades of condition-specific expertise, a full breadth of clinical support, and a wide variety of patient services.
Article
Understanding hereditary angioedema (HAE)
March 27, 2024
Breaking down what plan sponsors should know about HAE, its challenges and therapies.
Article
The benefits of timely and actionable specialty reporting
November 20, 2023
A comprehensive suite of reporting tools—and the right specialty partner to interpret data—can be invaluable for plan sponsors.